Dentium (A145720) Q3 2025 earnings summary

Executive summary

• Revenue for 2025 Q3 was ₩78.2 billion, a 17% decrease year-over-year due to weak sales in China and domestic markets amid economic downturn and intensified competition.

• Operating income dropped 49% year-over-year to ₩12.5 billion, reflecting reduced sales leverage and higher cost ratios.

• Net income fell 73% year-over-year to ₩3.9 billion, impacted by one-time overseas subsidiary tax expenses.

• Reviewed quarterly financial statements for the period ending September 30, 2025, with no material misstatements found under Korean IFRS 1034.

• The company operates primarily in dental medical devices, with a secondary energy segment focused on hydrogen fuel cells.

Financial highlights

• Gross margin declined to 62.8% from 68.7% year-over-year.

• Operating margin decreased to 15.9% from 25.7% year-over-year.

• SG&A expenses fell 10% year-over-year, with advertising expenses down 57%.

• EBITDA for the quarter was ₩18.6 billion, down ₩11.2 billion year-over-year.

• Revenue for the nine months ended September 30, 2025, was ₩184.0B, down from ₩229.3B year-over-year.

Outlook and guidance

• Ongoing economic weakness in China and domestic markets expected to continue affecting demand.

• Anticipates gradual sales recovery in Korea by 2026 and continued growth in Vietnam and Thailand.

• Plans to strengthen localization strategies in China and expand supply chain operations.

• Management continues to monitor market and financial risks, focusing on capital structure optimization and cost competitiveness.